PharmaMar: Sylentis Announces New Preclinical and Clinical Data for its SYL1001 Molecule During ARVO 2017

MADRID, May 9, 2017 /PRNewswire/ --

In the framework of the Annual Congress of the Association for Research in Vision and Ophthalmology 2017 (ARVO), being held from the 7-11 of May in Baltimore (USA), Sylentis, a pharmaceutical company from the PharmaMar Group (MCE: PHM), presents new preclinical and clinical developments with its molecule SYL1001 for the treatment of dry eye disease. This is a product based on the novel technology RNA interference (RNAi), developed for the treatment of the signs and symptoms of this pathology.

     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

This Congress will bring together more than 11,000 top eye and vision researchers and clinicians from around the world to explore cutting-edge basic and clinical science. "We are proud to be able to present our results to such a well prepared audience. We trust our technology, innovative in its field, and we hope thatSYL1001 will soon be a real alternative for treating millions of people that suffer from dry eye disease around the world", states Ana Isabel Jiménez, R&D Director of Sylentis.

Accordingly, Sylentis participates at this event with the presentation of data from various clinical and preclinical trials. On one hand, the stability results of SYL1001 in different commercial containers. The stability of the compound in various containers and conditions through time concludes that all the formats analyzed guarantee the integrity and specifications of the product.

On the other hand, Sylentis has presented the results of the study of this product in animal models, to evaluate its efficacy in the treatment of the symptoms and signs of dry eye disease. These patients have a deficit of mucine, a protein found in tears, a low density in the goblet cells and inflammation of the ocular surface. These studies have concluded that SYL1001, apart from reducing the feeling of ocular discomfort, it also improves the quality of the tear and reduces inflammation. In animal models, the statistical increase in the levels of mucine (MUC5A+) present on the eye´s surface has also been demonstrated, allowing for the formation of a tear film. In this same study, an increase in the density of goblet cell (those producing and secreting mucine) and also in tear secretion was observed. The inflammatory mediators of the eye surface also decreased after treatment.

Finally, the Company presents a third study that demonstrates the existing correlation between the preclinical and clinical results in the search for the optimum and most efficient dose. Both, in animal and human models, the concentration of 1.125% of SYL1001 was observed to be the most efficient, along with a very low incidence of adverse events.

Principle studies of Sylentis to be presented at ARVO 2017:

• Stability study of SYL1001 eye drops (a siRNA compound) for DED in different containers (Posterboard Number: 476- A0401) 

Session: 7th of May of 2017, from 13:30 to 15:15 hours. Lead author: Verónica Ruz, et al. Regulatory Affairs, Sylentis, Spain.

• Efficacy of SYL1001 in different animal models of Dry Eye Disease (Posterboard number: 458- A0383)

Session: 7th of May of 2017, from 13:30 to 15:15 hours. Lead author: Ana Isabel Jiménez et al. R&D, Sylentis, Spain.

• Clinical and preclinical study correlation for SYL1001, a new treatment for dry eye disease (Posterboard number: 2670- A0260)

Session: 9th of May of 2017, from 8:30 to 10:15 hours. Lead author: María Victoria González et al. Clinical Department, Sylentis, Spain.

Contacts: Media Relations (+ 34-638-79-62-15) and Investor Relations (+34-914-444-500)

SOURCE PharmaMar